Short Interest in Lonza Group Ag (OTCMKTS:LZAGY) Drops By 50.0%

Lonza Group Ag (OTCMKTS:LZAGYGet Free Report) was the target of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 27,683 shares, a decrease of 50.0% from the May 14th total of 55,395 shares. Based on an average trading volume of 135,751 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the company’s stock are short sold.

Lonza Group Stock Performance

OTCMKTS LZAGY traded down $0.88 during trading on Friday, reaching $61.53. 40,399 shares of the company’s stock were exchanged, compared to its average volume of 74,428. The business has a 50 day moving average price of $63.17 and a 200-day moving average price of $65.52. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.24 and a quick ratio of 1.77. Lonza Group has a fifty-two week low of $58.53 and a fifty-two week high of $73.85.

Analyst Ratings Changes

Separately, Zacks Research upgraded Lonza Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Lonza Group has an average rating of “Moderate Buy”.

Check Out Our Latest Stock Report on Lonza Group

About Lonza Group

(Get Free Report)

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

Recommended Stories

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.